| |
| |
|
| Insider
Information: |
Spiegelman Daniel K |
| Relationship: |
Director |
| City: |
|
| State: |
|
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
155,668 |
|
|
Indirect Shares
|
6,673 |
|
|
| Direct
Value |
$5,250,478 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
162,341 |
|
|
| Total
Value |
$5,250,478 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
CV Therapeutics Inc |
CVTX |
SVP, CFO |
2009-04-09 |
67,489 |
2009-04-09 |
6,673 |
Premium* |
|
|
Cascadian Therapeutics, Inc |
CASC |
Director |
2018-03-09 |
0 |
2009-12-04 |
0 |
Premium* |
|
|
Biomarin Pharmaceutical Inc |
BMRN |
EVP, Chief Financial O... |
2019-04-30 |
47,686 |
2012-05-29 |
0 |
Premium* |
|
|
Relypsa Inc |
RLYP |
Director |
2016-09-01 |
0 |
2015-06-04 |
0 |
Premium* |
|
|
Myriad Genetics Inc |
MYGN |
Director |
2023-06-02 |
40,493 |
2020-05-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-04-02 |
4 |
OE |
$10.45 |
$2,221,061 |
D/D |
188,958 |
143,076 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-02-24 |
4 |
A |
$0.00 |
$0 |
D/D |
72,633 |
101,077 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-09-02 |
4 |
OE |
$39.06 |
$624,960 |
D/D |
16,000 |
84,676 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-03-02 |
4 |
OE |
$39.06 |
$605,430 |
D/D |
15,500 |
84,176 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-04-30 |
4 |
A |
$51.26 |
$4,511 |
D/D |
88 |
79,366 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-03-03 |
4 |
A |
$0.00 |
$0 |
D/D |
10,500 |
79,278 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-05-15 |
4 |
D |
$122.78 |
$211,427 |
D/D |
(1,722) |
77,644 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-03-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,480 |
77,185 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2015-05-18 |
4 |
S |
$124.77 |
$256,905 |
D/D |
(2,059) |
75,585 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-03-22 |
4 |
D |
$81.36 |
$291,513 |
D/D |
(3,583) |
73,602 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-03-22 |
4/A |
D |
$81.36 |
$292,733 |
D/D |
(3,598) |
73,587 |
0 |
- |
|
| CVTX |
CV Therapeutics Inc |
SVP, CFO |
• – – |
2009-04-02 |
4 |
S |
$19.91 |
$2,807,887 |
D/D |
(141,029) |
73,439 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-06-04 |
4 |
A |
$0.00 |
$0 |
D/D |
13,800 |
73,134 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-03-03 |
4 |
OE |
$39.06 |
$312,480 |
D/D |
8,000 |
72,273 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2016-05-31 |
4 |
OE |
$39.06 |
$659,958 |
D/D |
16,896 |
71,235 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-07-02 |
4 |
S |
$64.00 |
$142,656 |
D/D |
(2,229) |
70,905 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-02-26 |
4/A |
A |
$0.00 |
$0 |
D/D |
12,615 |
70,215 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2018-02-26 |
4 |
A |
$0.00 |
$0 |
D/D |
12,529 |
70,129 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-11-20 |
4 |
A |
$65.89 |
$527 |
D/D |
8 |
68,760 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-10-30 |
4 |
A |
$65.75 |
$595 |
D/D |
9 |
68,752 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-08-06 |
4 |
A |
$62.17 |
$870 |
D/D |
14 |
68,751 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-03-05 |
4 |
S |
$82.93 |
$995 |
D/D |
(12) |
68,748 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-10-07 |
4 |
A |
$74.84 |
$449 |
D/D |
6 |
68,743 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2013-10-04 |
4 |
A |
$74.07 |
$370 |
D/D |
5 |
68,737 |
0 |
- |
|
| BMRN |
Biomarin Pharmaceutical I... |
EVP, Chief Financial Officer |
• – – |
2014-05-02 |
4 |
S |
$58.02 |
$644 |
D/D |
(11) |
68,737 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
